SG11201407787VA - A method of improving liver function - Google Patents
A method of improving liver functionInfo
- Publication number
- SG11201407787VA SG11201407787VA SG11201407787VA SG11201407787VA SG11201407787VA SG 11201407787V A SG11201407787V A SG 11201407787VA SG 11201407787V A SG11201407787V A SG 11201407787VA SG 11201407787V A SG11201407787V A SG 11201407787VA SG 11201407787V A SG11201407787V A SG 11201407787VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- victoria
- geelong
- street
- liver function
- Prior art date
Links
- 230000003908 liver function Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000005976 liver dysfunction Effects 0.000 abstract 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 abstract 1
- 229960004083 methazolamide Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651335P | 2012-05-24 | 2012-05-24 | |
| US201261666574P | 2012-06-29 | 2012-06-29 | |
| PCT/AU2013/000265 WO2013173859A1 (en) | 2012-05-24 | 2013-03-15 | A method of improving liver function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407787VA true SG11201407787VA (en) | 2014-12-30 |
Family
ID=49622927
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407787VA SG11201407787VA (en) | 2012-05-24 | 2013-03-15 | A method of improving liver function |
| SG10201705388XA SG10201705388XA (en) | 2012-05-24 | 2013-03-15 | A Method Of Improving Liver Function |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201705388XA SG10201705388XA (en) | 2012-05-24 | 2013-03-15 | A Method Of Improving Liver Function |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20150150855A1 (https=) |
| EP (1) | EP2854807A4 (https=) |
| JP (2) | JP6360826B2 (https=) |
| KR (1) | KR20150023405A (https=) |
| CN (2) | CN104487073A (https=) |
| BR (1) | BR112014029308A2 (https=) |
| CA (1) | CA2874513A1 (https=) |
| CO (1) | CO7160082A2 (https=) |
| HK (1) | HK1209051A1 (https=) |
| MX (1) | MX362111B (https=) |
| NZ (2) | NZ702645A (https=) |
| RU (1) | RU2653478C2 (https=) |
| SG (2) | SG11201407787VA (https=) |
| WO (1) | WO2013173859A1 (https=) |
| ZA (1) | ZA201408704B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2106260T3 (pl) | 2007-01-25 | 2018-06-29 | NAIA Metabolic, Inc. | Środki uwrażliwiające na insulinę i sposoby leczenia |
| US20150174108A1 (en) * | 2012-05-24 | 2015-06-25 | Vera Pharmaceuticals Ltd | Method of weight reduction |
| US10039752B2 (en) * | 2016-07-21 | 2018-08-07 | Cipla Limited | Methazolamide for the treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2783241A (en) * | 1957-02-26 | S-acylimino-x-substituted-az-i | ||
| DE10035227A1 (de) * | 2000-07-20 | 2002-01-31 | Solvay Pharm Gmbh | Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind |
| EA010422B1 (ru) | 2003-08-01 | 2008-08-29 | Янссен Фармацевтика Н.В. | Замещённые индол-о-глюкозиды |
| PL2106260T3 (pl) * | 2007-01-25 | 2018-06-29 | NAIA Metabolic, Inc. | Środki uwrażliwiające na insulinę i sposoby leczenia |
| US20150174108A1 (en) * | 2012-05-24 | 2015-06-25 | Vera Pharmaceuticals Ltd | Method of weight reduction |
-
2013
- 2013-03-15 BR BR112014029308A patent/BR112014029308A2/pt not_active Application Discontinuation
- 2013-03-15 WO PCT/AU2013/000265 patent/WO2013173859A1/en not_active Ceased
- 2013-03-15 SG SG11201407787VA patent/SG11201407787VA/en unknown
- 2013-03-15 SG SG10201705388XA patent/SG10201705388XA/en unknown
- 2013-03-15 NZ NZ702645A patent/NZ702645A/en not_active IP Right Cessation
- 2013-03-15 EP EP13794766.9A patent/EP2854807A4/en not_active Withdrawn
- 2013-03-15 CN CN201380033568.7A patent/CN104487073A/zh active Pending
- 2013-03-15 KR KR20147035500A patent/KR20150023405A/ko not_active Withdrawn
- 2013-03-15 CA CA2874513A patent/CA2874513A1/en not_active Abandoned
- 2013-03-15 US US14/403,507 patent/US20150150855A1/en not_active Abandoned
- 2013-03-15 CN CN201811294792.2A patent/CN109498623A/zh active Pending
- 2013-03-15 MX MX2014014317A patent/MX362111B/es active IP Right Grant
- 2013-03-15 HK HK15109811.1A patent/HK1209051A1/xx unknown
- 2013-03-15 RU RU2014152196A patent/RU2653478C2/ru not_active IP Right Cessation
- 2013-03-15 JP JP2015512968A patent/JP6360826B2/ja not_active Expired - Fee Related
- 2013-03-15 NZ NZ723206A patent/NZ723206A/en not_active IP Right Cessation
-
2014
- 2014-11-26 ZA ZA2014/08704A patent/ZA201408704B/en unknown
- 2014-12-19 CO CO14279764A patent/CO7160082A2/es unknown
-
2017
- 2017-12-22 JP JP2017246443A patent/JP6412241B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-12 US US15/952,058 patent/US20180333399A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ723206A (en) | 2018-02-23 |
| HK1209051A1 (en) | 2016-03-24 |
| MX2014014317A (es) | 2015-08-10 |
| US20150150855A1 (en) | 2015-06-04 |
| CN109498623A (zh) | 2019-03-22 |
| RU2653478C2 (ru) | 2018-05-08 |
| EP2854807A1 (en) | 2015-04-08 |
| EP2854807A4 (en) | 2016-03-16 |
| CN104487073A (zh) | 2015-04-01 |
| SG10201705388XA (en) | 2017-07-28 |
| RU2014152196A (ru) | 2016-07-20 |
| WO2013173859A1 (en) | 2013-11-28 |
| ZA201408704B (en) | 2018-07-25 |
| JP6360826B2 (ja) | 2018-07-18 |
| NZ702645A (en) | 2016-08-26 |
| JP2015517534A (ja) | 2015-06-22 |
| JP2018090589A (ja) | 2018-06-14 |
| CA2874513A1 (en) | 2013-11-28 |
| KR20150023405A (ko) | 2015-03-05 |
| MX362111B (es) | 2019-01-07 |
| CO7160082A2 (es) | 2015-01-15 |
| US20180333399A1 (en) | 2018-11-22 |
| BR112014029308A2 (pt) | 2017-06-27 |
| JP6412241B2 (ja) | 2018-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407200TA (en) | Liquid formulation | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201406787TA (en) | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies | |
| SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
| SG11201407427WA (en) | Extreme pcr | |
| SG11201909009TA (en) | Catheter securement device with window | |
| SG11201406903SA (en) | Cell culture compositions and methods for polypeptide production | |
| SG11201407747QA (en) | A method and apparatus for facilitating the management of health and security | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
| SG11201408185UA (en) | Improved frame for climbing screen | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
| SG11201407800SA (en) | Selective binding of biological targets to solid phase ureides | |
| SG11201408163VA (en) | Modified fibronectin fragments or variants and uses thereof | |
| SG11201408119PA (en) | Systems and methods for data center cooling and water desalination | |
| SG11201909003YA (en) | Integrated vascular access device and anchor pad | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
| SG11201407801VA (en) | Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations | |
| SG11201406745VA (en) | Methods of therapeutic monitoring of phenylacetic acid prodrugs | |
| SG11201407924RA (en) | METHOD OF TREATING <i>SCEDOSPORIUM SPP</i>. INFECTION | |
| SG11201809541UA (en) | Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer |